Investors

Media

Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company.

For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com.



View all releases Recent Press Releases

Sep 22, 2014 Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan
Sep 16, 2014 EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema
Sep 4, 2014 Regeneron Announces Submission of Application for EYLEA® (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion
Aug 31, 2014 Regeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014
Aug 25, 2014 Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014
Aug 19, 2014 Regeneron Announces Upcoming 2014 Investor Conference Presentations
Aug 11, 2014 EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
Aug 5, 2014 Regeneron Reports Second Quarter 2014 Financial and Operating Results
Jul 30, 2014 Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Jul 30, 2014 Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia


Close
Form content here please :)